Alnylam pushes RNAi program into PhI; Aveo takes a smaller office in Cambridge;

@FierceBiotech: The FierceBiotech panel: Top research execs tackle the fast-changing field of cancer drug R&D at BIO 2015. More | Follow @FierceBiotech

@JohnCFierce: This should be interesting: Can PureTech and its high-profile board raise $160M in London? More | Follow @JohnCFierce

> Cambridge, MA-based Alnylam ($ALNY) launched a Phase I clinical trial with ALN-AS1, an RNAi therapy targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyrias. Release

> Aveo Oncology ($AVEO) is relocating into smaller offices, taking 5,000 square feet at One Broadway in Cambridge, MA. Release

Medical Device News

@FierceMedDev: ICYMI: Sequenom stares down suit from Indian genomics firm. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: NIH announces winning teams of Neuro Startup Challenge to commercialize its inventions. Report | Follow @VarunSaxena2

@EmilyWFierce: Study: Gilead's Harvoni could save U.S. and Europe billions in worker productivity. More from FiercePharma | Follow @EmilyWFierce

> SI-Bone raises $21M, brings on new CFO to grow iFuse implant sales. More

> Strong data from Medtronic's latest TAVR caps excellent week for the devices at European conference. Report

Pharma News

@FiercePharma: Bionic turtle offers glimpse into future of 3-D printing. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA blesses Baxter saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Want the U.K.'s NHS to quickly adopt new products, drugmakers? There's an office for that. Item | Follow @CarlyHFierce

> Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadoline. Item

> Investors: GSK chief Witty is safe for now, but one more strike and he's out. More

> The legal death of Actavis' Namenda strategy spells doom for the 'hard switch.' Article

Pharma Manufacturing News

> Law enforcement makes another illegal pharma supply chain bust; 2nd in U.S. in 8 days. More

> Singapore moving to meet pharma manufacturing demand for high-quality water. Report

> Strides Arcolab pays $287M for Aspen Pharmacare's Australian business. Article

> Report: Russia quickly becoming a major source of online fake pharma. Item

> Cipla pulls levalbuterol on FDA warning; Wockhardt removes other drugs on concerns. Story

Animal Health News

> Wal-Mart hailed for leadership on animal welfare. Story

> Animal health, production in St. Joseph, MO, ranks fourth in U.S. metro ag economies. Report

> Patterson posts record quarterly results amid shift toward animal health. Story

> Bionic turtle offers glimpse into future of 3-D printing. Item

> Chicken producer Sanderson says FDA's crackdown on antibiotics lacks 'reliable science.' Article

Biotech IT News

> PatientsLikeMe nabs Merck informatics veteran to lead R&D. More

> Gentleman aims to use 23andMe's R&D blank slate to tip in vivo-in silico testing balance. Story

> Trialbee raises $5M to mount U.S. expansion of online trial enrollment business. Item

> Celgene taps Cypher Genomics to spot biomarkers in datasets. Article

> Hedge fund aims algorithms at pharma patents to sink stocks. Report

Drug Delivery News

> Nanoparticles tagged with amino acids help diagnose glioblastoma to someday target drugs. News

> Pacira's liposomal-encased bupivacaine gets positive reviews at breast cancer conference. Report

> European researchers developing implantable, insulin-controlling capsule to fight diabetes. More

> FDA approves long-acting formulation of J&J schizophrenia med. Item

> Data-gathering insulin pen maker Companion pulls in Series B led by Eli Lilly. Article

Pharma Asia News

> Australia zeroes in on pharma in transfer-pricing probe. News

> Heavyweight Chinese consortium buys San Diego-based Ambrx. Article

> Pakistan seen as hot pharma growth market. Story

> CBMG says China and U.S. growing quickly closer in biotech space. More

> China Medical Systems in Greater China deal with Finland's Faron on respiratory candidate. Article

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.